Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
Key takeaways of recent quarter & conference call highlights
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Filing marks first protein-based vaccine submitted to MHRA for authorization
UFlex has committed close to US $ 10 million towards various initiatives at its overseas and Indian plants to repurpose plastic waste
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Subscribe To Our Newsletter & Stay Updated
